API | asciminib

asciminib (Scemblix) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Fast Track ^FDA Accelerated Approval ^FDA Priority Review ^FDA

Active Ingredient History

NOW

Now

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Breakpoint cluster region protein (Homo sapiens) ^UniProt
- Tyrosine-protein kinase ABL1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (12)

Research & Development (12)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (2)

Leukemia, Myeloid, Acute (approved 2021)

Philadelphia Chromosome (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Biliary Tract Neoplasms (Phase 1/Phase 2)

Hematologic Diseases (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 3)

Neoplasms (Phase 1/Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 17
# of Trial Organizations: 12

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue